Upstream Bio details Phase 3 strategy for verekitug; positive Phase 2 asthma and CRSwNP data

Upstream Bio, Inc.

Phase 3 development plan for verekitug: high-dose quarterly regimen (up to 400 mg q12w) in severe asthma and CRSwNP; initiation in Q1 2027.
Phase 2 VALIANT asthma trial met primary endpoint: AAER reduction 56% (p<0.0003) with 100 mg q12w; safety profile favorable.
Phase 2 VIBRANT CRSwNP data: placebo-adjusted NPS reduction -1.95 (WOCF) and NCS reduction -0.96 at week 24.
Cash position $341.5M as of Dec 31, 2025, expected to fund operations through 2027.
Q4 2025 net loss $42.5M vs $21.2M a year ago; R&D expenses rose to $40.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Upstream Bio, Inc. reported financial results for the quarter and year ended December 31, 2025.

Period: the quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026, Upstream Bio, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Upstream Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-125057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.